Verrica Pharmaceuticals' Molluscum Contagiosum Topical Solution Gets FDA Approval
22 7월 2023 - 6:05AM
Dow Jones News
By Denny Jacob
Verrica Pharmaceuticals on Friday said the Food and Drug
Administration approved Ycanth topical solution to treat molluscum
contagiosum in adults and patients ages two and up.
The dermatology therapeutics company said it plans to make
Ycanth available by September.
Molluscum contagiosum is an infection caused by a poxvirus,
which can result in a benign, mild skin disease characterized by
growths on the body.
Chief Executive Ted White said molluscum contagiosum primarily
affects children and is commonly transmitted in households, schools
and swimming pools through skin-to-skin contact given its highly
contagious nature.
Trading of the company's stock was halted at 3:58 p.m. ET ahead
of the news.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
July 21, 2023 16:50 ET (20:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Verrica Parmaceuticals (NASDAQ:VRCA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
